Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

December 8, 2021

Study Completion Date

January 26, 2022

Conditions

Non-small Cell Lung CancerNSCLC

Interventions

DRUG

AMG 160

AMG 160 administered as an intravenous (IV) infusion

Trial Locations (4)

Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna

Chris OBrien Lifehouse, Camperdown

Landeskrankenhaus Salzburg, Salzburg

University of Texas MD Anderson Cancer Center, Houston